|
See related Primacor inj information |
|
|
|
Manufacturer |
sanofi-aventis |
|
Distributor |
Hong Kong: LF Asia |
|
Contents |
Milrinone lactate |
|
Indications |
Short-term IV therapy of CHF. |
|
Dosage |
Loading dose: 50 mcg/kg IV (over 10 min). Maintenance: 0.375-0.75 mcg/kg/min as continuous IV infusion. Max: 1.13 mg/kg/day. |
|
Contraindications |
Severe obstructive heart & valvular disease. |
|
Special Precautions |
Acute phase of post-MI. Monitor BP, heart rate, blood creatinine & water-electrolyte balance during therapy. Renal impairment. Patients at high risk of heart rhythm disorders. Patients w/ heart failure. |
|
Adverse Drug Reactions |
Headache, ventricular & supraventricular arrhythmias, hypotension, chest pain, rash.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
C01CE02 - milrinone ; Belongs to the class of phosphodiesterase inhibitors. Used in the treatment of heart failure. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Primacor injection |
|
Primacor 1 mg/1 mL x 10 mL x 10's |
|
|
|
Manufacturer: |
sanofi-aventis |
|
Distributor: |
Hong Kong: LF Asia |
|
|
|
|
